SS
ADAP

SBI Securities’s Adaptimmune Therapeutics ADAP Stock Holding History

SBI Securities’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$1 – 4014
2025
Q3 		$1 Hold
10
– – ﹤0.01% 4159
2025
Q2 		$2 Hold
10
– – ﹤0.01% 4109
2025
Q1 		$2 Buy
+10
New +$5 ﹤0.01% 4079

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.41B AUM 41.48% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

SBI Securities's ADAP Position: Q4 2025 in Review

SBI Securities sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 10 shares — an estimated $1 sold.

SBI Securities first reported a position in ADAP in Q1 2025 and held it in 3 quarters. The position peaked at $2 in Q2 2025. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • SBI Securities reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SBI Securities sold 10 Adaptimmune Therapeutics shares in Q4 2025, an estimated $1.
  • SBI Securities first reported a position in Adaptimmune Therapeutics in Q1 2025 and held it in 3 quarters.
  • SBI Securities's Adaptimmune Therapeutics position peaked at $2 in Q2 2025.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on SBI Securities's 13F filing for Q4 2025, filed 3 Feb 2026.